EGFR and non-small cell lung carcinoma: To determine this, we first investigated whether CBD has any particular effects on NSCLC cell lines with diverse genetic backgrounds such as A549 cells (KRAS mutation, P53 wide-type), NCI-H2228 (EML4-ALK variant 3, P53 Q331* mutation) and HCC-827 (EGFR exon19 deletion mutant, inactivation P53 mutation).